Clinical and GCF outcomes of Minimally-invasive non-surgical periodontal therapy in teeth with bone loss to the apex. A prospective study

Abstract

AimsThe aim of this prospective study was to assess the potential benefits of minimally-invasive non-surgical therapy (MINST) in the healing of intrabony defects reaching the apex. MethodsTwenty systemically healthy patients with stage III-IV periodontitis and with at least one tooth with an intrabony defect reaching the apex were included in the study. Step 1 and 2 periodontal therapy including MINST were provided to all patients and patients were then followed up to 12 months post-treatment. Clinical parameters, standardised periapical radiographs and gingival crevicular fluid (GCF) samples were collected at test and control sites. 31 biomarkers were analysed. ResultsThree cases did not have the 12-months review (2 drop-outs and 1 tooth lost due to fracture). Despite significant improvements in clinical and radiographic parameters, the majority of defects still had PPD>5mm at the 12-months reassessment, therefore needing further treatment, including endodontic treatment in some cases. A pattern of increase in GCF biomarkers associated with a senescent secretory phenotype was detected immediately after treatment in test sites, with a decrease up to 12 months. An increase in IL-1β and MMP-3 in particular seems to be associated with increased risk to need endodontic treatment post-MINST. ConclusionsThe treatment of teeth with unfavourable prognosis and bone loss to the apex with MINST leads to PPD reduction, CAL gain and reduction in radiographic defect depth 12 months after treatment. However, MINST alone may not be sufficient in terms of defects resolution in most of these cases. Clinical significanceThe treatment of teeth with unfavorable prognosis and bone loss to the apex (hopeless) using MINST may lead to consistent PPD reduction, CAL gain and radiographic defect depth reduction after 12 months. However, adjunctive therapies may be necessary to achieve endpoints of therapy in these defects. GCF biomarkers may clarify healing patterns.